Global Acute Bacterial Skin & Skin Structure Infections Treatment Market (ABSSI) By Infection Type (Hospital-Acquired ABSSI and Community-Acquired ABSSI), By Drug Type (Oral and Parental Antibiotics), By Route of Administration (Oral, Parental, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The global acute bacterial skin & skin structure infections treatment market size is expected to be worth around USD 23.2 Bn by 2032 from USD 9.5 Bn in 2022, growing at a CAGR of 5.2 % during the forecast period from 2022 to 2032.

Acute Bacterial Skin and Skin Structure Infections are known to be bacterial infections of the skin and interconnected tissues. These infections may be uncomplicated skin infections or complicated skin infections.

The uncomplicated group involves impetiginous lesions, simple abscesses, furuncles, and cellulitis mainly caused by streptococcus pyogenes and staphylococcus aureus.

Antibiotic treatments are preferred for the treatment of skin and skin structure infections, but an escalation in antimicrobial resistance between gram-negative (-) and gram-positive (+) bacteria with Methicillin Resistant Staphylococcus Aureus (MRSA) has become truly difficult in treating Acute Bacterial Skin & Skin Structure Infections (ABSSSI). Thus the development of new drugs to act against resistant microbes is an essential need of the time.

In Addition to it, the prevalence of bacterial skin infections is increasing in developing nations like India, China, and certain regions of the Middle East & Africa, and Latin America.

Complete research in the enhancement of novel treatment choices and a large account of potential drugs in late and middle-stage development is predicted to generate a profitable habitat for acute bacterial skin and skin structure infections treatment market expansion across the forecast period.

The rising financial burden of ABSSSI involving the indirect and direct price of treatment, along with extended treatment periods and insufficiency of efficient drugs in acting towards skin infections, has granted considerable unsatisfied needs for this market growth.

This is generating a high range of options for major players to take entry in the Acute bacterial skin and skin structure infections treatment market by developing new drugs against MRSA Methicillin Resistant Staphylococcus Aureus with an intention to deal against resistant bacteria, thus reducing the financial burden of the treatment cost.

This is linked to the rising prevalence of hospital-acquired ABSSSI and the demand for effective drugs, which will increase the acute bacterial skin and skin structure infection treatment market growth over the forecast period.

Market Scope

Infection Type Analysis

Based on type, the global acute bacterial skin and skin structure infection market are segmented into hospital-acquired ABSSSI and community-acquired ABSSSI. Hospital-acquired ABSSSI is generally brought upon admission to a hospital that has not existed in the patient before hospitalization.

These infections have become a huge problem for healthcare providers as they are among the strong reasons for the risk of mortality rates worldwide. MRSA has been the reason for more infections as well, as increasing resistance against this bacterium is resulting in the growth of hospital-acquired acute bacterial skin and skin structure infections. Eradication of the causative pathogens requires effective antibiotic therapy against the most likely microorganism.

During the forecast period, Hospital-Acquired ABSSSI is estimated to be the fastest-expanding segment among all types. Thus it will boost the growth of the acute bacterial skin and skin structure infections treatment marke

By Drug Type

Based on drug type, the global acute bacterial skin and skin structure infection market are segmented into oral and parental antibiotics. In the past times, the IDSA (Infectious Diseases of America) published practice guidelines for the diagnosis and management of acute bacterial skin and skin structure infections.

As per this publishment, IDSA precedes the food and drug administration’s approval of much newer antibiotic treatment of ABSSSIs, involving oritavancin, delafloxacin, dalbavancin, and tedizolid.

These guidelines classify ABSSSIs into nonpurulent and purulent categories. Erysipelas and cellulitis are considered nonpurulent, while abscesses are purulent. Vancomycin, tigecycline, linezolid, daptomycin, telavancin, and ceftaroline are all considered appropriate antimicrobial agents for the treatment of severe purulent infections, while doxycycline and trimethoprim-sulphamethoxazole are recommended for moderate purulent infections. Cefazolin and Clindamycin are preferred for MSSA (Methicillin Susceptible Staphylococcus Aureus).

While cephalexin and dicloxacillin are for moderate infections, Vancomycin is a first-line treatment option for severe nonpurulent infections. Ceftolozane/tazobactam used in combination with metronidazole for Urinary tract infection

Although this antibiotic treatment has been used for decades, current understanding requires therapeutic drug monitoring of medication in patients with renal impairment and obese patients.

Based on API (Active Pharmaceutical Ingredient), Delafloxacin upholds the largest market share over the forecast period. Delafloxacin is generally used to treat various types of bacterial infections. This medication is derived from the class quinolone antibiotic treatment.

Next to Delafloxacin, Vancomycin is the most-used drug that holds the second largest market share of the ABSSSI treatment market.

Soft tissue infections, the emergence of resistance, ischemic ulcer, causative agents, severe infections, hospital-acquired, purulent wound infections, complicated intra-abdominal Infections, necrotic infections, staphylococcal infections, non-purulent infections, aureusskin infections, aureussurgical site infection, complications of infection, milder infections, moderate infections, pressure ulcer, gram-positive bacteria, gram-negative bacteria, acute skin infections, initial treatment failure are further driving factors responsible for the acute bacterial skin and skin structure infections treatment market growth.

By Route of Administration

Based on this segment, oral, topical, and parental are the routes of administration for acute bacterial skin and skin structure infection treatment products. As per the records, the parenteral routes reported holdings of maximum share in 2022 owing to penetration of novel products against the resistance of methicillin-resistant staphylococcus aureus, therapeutics benefits provided by the parental treatment, and short curative period as compared to the oral route of administration.

This creates a dominance of parental Products in the market, followed by the Oral route of administration holds a greater market share as compared to Topical. Physicians must be attentive to the management of patients who show some well-known risk factors.

A Randomized Controlled Trial (RCT) found that switching from intravenous vancomycin to oral linezolid shortened the overall duration of therapy for patients with MRSA-associated SSTIs, increasing patient benefit and overall cost to the health system.

According to a recent European retrospective study, patients with ABSSSIs have 20% of wound infections, and around 80% have cellulitis. Hence this segment will drive the acute bacterial skin and skin structure infections treatment market toward growth.

By Distribution Channel

Based on the distribution channel, the global acute bacterial skin and skin structure infections treatment market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy.

The Hospital segment registered the largest market share during the forecast period. Increased interaction with medical prescribers and other health professionals has accredited factors to all benefits that are increasing demand for this segment.

Followed by Hospital Pharmacies, Retail Pharmacies also generate a handsome revenue as compared to Online Pharmacies.

Key Market Segments

Based on Infection Type

• Hospital-acquired ABSSSIs
• Community-acquired ABSSSIs

Based on the Drug Type

• Oral Antibiotics
• Parental Antibiotics

Based on the Route of Administration

• Oral Route
• Parental Route
• Topical Route

Based on Distribution Channel Analysis

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Dynamics

Drivers

Increased R & D activities by the pharmaceutical companies and conduct of clinical  trials

The Global Acute Bacterial Skin and Skin Structure Infection Market size is expanding at a moderate pace with steady growth over recent years, and it is projected that the market will expand considerably in the forecasted period, i.e., 2023 to 2032.

Expanding development and research activities by pharmaceutical and biopharmaceutical companies to offer novel products and new treatment is an essential factor that is responsible for the growth of this market on a global scale. ABSSSI is a soft tissue and skin infection that affects the dermis, epidermis, and subcutaneous tissue.

The symptoms witnessed in acute bacterial skin and skin structure infection have wound infection, major cutaneous abscesses, burn infections, and extensive cellulitis occurring inside the minimum area of 75 cm2.

The disease caused by MRSA, MSSA, E. Coli, klebsiella pneumonia, klebsiella oxytoca, and streptococcus agalactiae pushes the ABSSI towards inclination for streptococcal antibiotics are the mainstay of treatment.

The FDA works consistently on the conduct of clinical trials and programs for ABSSSI.

Furthermore, a growing number of product approval from regulatory authorities is expected to stimulate the growth of the North American and Europe Acute Bacterial skin and skin structure infections acute bacterial skin and skin structure infections market.

Restraints

Antimicrobial resistance and strict regulatory policies slow down the market growth rate.

Antimicrobial resistance is the biggest challenge for antibiotic drugs to survive in the market for a long period; hence, from time to time, the new drug development process needs to be carried out by the key market players. Moreover, the acts by regulatory policies, such as the termination of patent licenses, hamper the market growth.

The pathways for antimicrobial resistance are listed below

• Limiting uptake of the drug
• Modifying a drug target
• Inactivating a drug
• Active drug efflux

Opportunity

Rising Patient Pool

A growing count of vagrant patients seeking treatment for skin and skin structure infections will additionally increase the development of the acute bacterial skin and skin structure infections market.

The infections market depends upon expanding the number of tough administrative arrangements by government bodies, strains of causative specialists, and patent termination.

For instance, in 2016, Allergan plc received US Food and Drug Administration (FDA) authorization for its supplemental New Drug Application (sNDA) for teflaro for ABSSSI punch in paediatrics.

In an observational study, lesion size determines the probability of treatment failure. The duration of infection also determines the probability of treatment failure.

The growing count of hospital-acquired acute bacterial skin and skin structure infections is a greater opportunity for key players to focus on new drug introduction in the parental route of administration, as parental antibiotics are mostly preferred to take under medical supervision. Surgical intervention is required when the strain of bacteria is resistant to the treatment.

Increasing cases of antimicrobial resistance provide the opportunity for new key players to enter a market with new drug development.

Trends

It is anticipated that Hospital Acquired ABSSI will hold a sizable market share in the process component segment

Infections acquired in the hospital sector that did not exist before the contract are known as hospital-acquired or Healthcare-Associated Infections (HCAIs). This may lead to prolonged stays in acute care hospitals.

For example, the study “Update on the Epidemiology of Healthcare-Acquired Bacterial Infections: Focus on Complicated Skin and Skin Structure Infections,” published in the Journal of Antimicrobial Chemotherapy in November 2021, estimates that 834,000 adult inpatients in National Health Service hospitals in England experience healthcare-associated infections (HCAIs) annually, accounting for 7.1 million bed days (21 percent of total annual bed days).

Moreover, as per the same source, the prevalence of hospital-acquired ABSSSI is estimated to be 6.1%. The most common infections include Surgical Site Infections (SSIs) and Skin Soft Tissue Infections (SSTIs).

COVID-19 Impact Analysis

The global supply chain of pharmaceuticals was impacted by the COVID-19 pandemic, impacting the acute bacterial skin and skin structure infections market.

However, COVID-19 patient’s bacterial skin and skin structure infections deteriorate, according to a study titled “Hospital-acquired Skin and Skin-structure Infection in COVID-19 Infected Patient with Prolonged Hospitalization” that was published in Acta Medica Indonesia in January 2021.

They are needed to extend hospital stays in response to the need for more treatment alternatives and to foresee market expansion during COVID-19. Thus, COVID-19 has a big impact on the market for acute bacterial skin and skin structure infections (ABSSSI).

Therefore, the COVID-19 pandemic significantly impacted the acute bacterial skin and skin structure infections market. The rising awareness and prevalence of ABSSSI, as well as growing development and research activities by biopharmaceutical and pharmaceutical companies to offer new products and novel treatments, all contribute to global Acute bacterial skin and skin structure infections market growth.

Regional Analysis

North America to continue its domination over the forecast period

Based on the segment of regional analysis, the global acute bacterial skin and skin structure infection treatment market are Segmented into these key regions North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, and Middle East & Africa.

Out of these regions, the dominance of North America continues in the acute bacterial skin and skin structure infections treatment market during the forecast period due to increased development activity, extensive research, product pipeline, novel product launches, and R&D spending.

For instance, the study titled “Development of New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections posted by ClinicalTrials.gov posted on January 2020 under the clinical development for the drug Dalbavancin from the allergen pharmaceutical in the United States.

Therefore, the count of drugs under clinical trials is estimated to expand the product launch over the prediction period of estimated market growth. Still, the growing product approval by regulatory authorities and product pipeline is predicted to boost market growth over the forecast period.

In 2022 Paladin Labs Inc., a subsidiary of Endo International plc, initiated Xydalba (dalbavancin for injection), a 30-minute IV (intravenous) therapy in Canada for acute bacterial skin and skin structure infections that can be administered as a single or two-dose regimen.

Thus all such factors are predicted to raise the market in North America over the forecast period.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The “Global Acute Bacterial Skin and Skin Structure Infections Treatment Market involves some of the major players such as Fresenius SE & Co. KGaA, Glenmark Pharmaceuticals Ltd., Melinta Therapeutics, Inc., Allergan plc.

The other key companies are Teva Pharmaceutical Industries Ltd, Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Merck & Co. Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.) and Cadila Healthcare Ltd., Aurobindo Pharma Ltd., etc. These market players are involved in collaborations, partnerships, and new product development to broaden their product portfolio.

Recent Developments

In February 2019, after receiving approval from Food and Drug Administration, Paratek Pharmaceuticals Inc. introduced NUZYRA IV, an oral antibiotic in the Treatment of Acute Bacterial Skin and Skin Structure Infection.

In June 2022, Basilea Pharmaceutica Ltd revealed today positive topline results for the phase 3 ERADICATE study, investigating Ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by SAB (Staphylococcus aureus).

GlaxoSmithKline plc, a United Kingdom-based pharmaceutical and biotechnology company, announced in October 2019 that it would evaluate gepotidacin, the first of a new chemical class of antibiotics called bacterial triazaacenaphthylene topoisomerase inhibitors. Announced the start of Phase III clinical trial.

Below is the list of prominent players in the Global Acute Bacterial Skin & Skin Structure Infection Treatment Market.

Market Key Players

• Paratek Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Melinta Therapeutics, Inc.
• AbbVie Inc.
• Sandoz International GmbH
• Glenmark Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Aceragen, Inc.
• Pfizer Inc.
• Allergen
• Cumberland Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Accord Healthcare ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)
• Cadila Healthcare Ltd.
• Other Key Players